SEARCH

SEARCH BY CITATION

References

  • 1
    HIV surveillance–United States, 1981-2008. MMWR Morb Mortal Wkly Rep 2011; 60: 689693.
  • 2
    Chesson HW, Gift TL, Owusu-Edusei K, Jr, Tao G, Johnson AP, Kent CK. A brief review of the estimated economic burden of sexually transmitted diseases in the United States: inflation-adjusted updates of previously published cost studies. Sex Transm Dis 2011; 38: 889891.
  • 3
    Schackman BR, Gebo KA, Walensky RP et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990997.
  • 4
    Palella FJ, Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 5
    de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 2010; 85: 7590.
  • 6
    Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res 2010; 85: 201209.
  • 7
    Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006; 12: 10751090.
  • 8
    Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health Syst Pharm 2004; 61: 25072522.
  • 9
    Kong HH, Myers SA. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. Dermatol Ther 2005; 18: 5866.
  • 10
    Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23: 173182.
  • 11
    Luther J, Glesby MJ. Dermatologic adverse effects of antiretroviral therapy: recognition and management. Am J Clin Dermatol 2007; 8: 221233.
  • 12
    Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005; 28: 5366.
  • 13
    Been-Tiktak AM, Boucher CA, Brun-Vezinet F et al. Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. Int J Antimicrob Agents 1999; 11: 1321.
  • 14
    Bonnet F, Lawson-Ayayi S, Thiebaut R et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997–1999. Clin Infect Dis 2002; 35: 12311237.
  • 15
    Cameron DW, da Silva BA, Arribas JR et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198: 234240.
  • 16
    Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 14231430.
  • 17
    Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One 2010; 5: e9183.
  • 18
    Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803813.
  • 19
    D'Aquila RT, Hughes MD, Johnson VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996; 124: 10191030.
  • 20
    DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 10381046.
  • 21
    Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251260.
  • 22
    Haas DW, Fessel WJ, Delapenha RA et al. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2001; 183: 392400.
  • 23
    Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23: 22892300.
  • 24
    Lennox JL, Dejesus E, Berger DS et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 3948.
  • 25
    Montaner JS, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279: 930937.
  • 26
    Pozniak AL, Morales-Ramirez J, Katabira E et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24: 5565.
  • 27
    Yeni P, Cooper DA, Aboulker JP et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368: 287298.
  • 28
    Chou VB, Omer SB, Hussain H et al. The costs associated with adverse event procedures for an international HIV clinical trial determined by activity-based costing. J Acquir Immune Defic Syndr 2007; 46: 426432.
  • 29
    Wilson RD. Mortality and cost of pneumonia after stroke for different risk groups. J Stroke Cerebrovasc Dis 2012; 21: 6167.
  • 30
    Palella FJ, Jr, Gange SJ, Benning L et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24: 16571665.
  • 31
    Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 4155.
  • 32
    Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporates the propensity score. Am Stat 1985; 39: 3338.
  • 33
    D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49: 14291433.
  • 34
    Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov/cpi/ (accessed 21 October 2010).